CABALETTA BIO, INC. (CABA) News
Filter CABA News Items
CABA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest CABA News From Around the Web
Below are the latest news stories about CABALETTA BIO INC that investors may wish to consider to help them evaluate CABA as an investment opportunity.
Cabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measuresKey Insights Significantly high institutional ownership implies Cabaletta Bio's stock price is sensitive to their... |
Cabaletta Bio to Participate in Upcoming Investor Conferences in DecemberPHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following investor conferences in December: 7th Annual Evercore HealthCONx Conference: Fireside chat on Wednesday, December 4, 2024, at 7:55 a.m. ET in Coral Gables, FL. Members of |
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024– CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – – Compelling clinical responses observed in lupus and myositis patients with up to six months of follow-up; first SSc patient demonstrated an emerging, drug-free clinical response – – All eight patients with active, refractory autoimmune disease discontinued all immunosuppressants prior to CABA-201 infusion |
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update– Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in oral and poster presentations at ACR Convergence 2024 – – 16 patients enrolled with 10 patients dosed as of November 12 across the RESET™ clinical development program; 40 U.S. clinical sites actively recruiting patients – – Data permitting, anticipate meeting with the FDA in 2025 regarding potential registrational program designs for CABA-201 |
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation ConferencePHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Monday, November 11, 2024, at 10:00 a.m. ET in Boston, MA. A live webcast of the presentation will be avai |
We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
State Street Corp's Strategic Reduction in Cabaletta Bio Inc HoldingsOn September 30, 2024, State Street Corp executed a significant transaction by reducing its holdings in Cabaletta Bio Inc (NASDAQ:CABA), a clinical-stage biotechnology company. This move reflects a strategic adjustment in State Street Corp's investment portfolio, despite the trade having a minimal immediate impact on its overall position. State Street Corp, headquartered at One Lincoln Street, Boston, MA, is a prominent investment firm known for its robust investment strategies that focus primarily on long-term value creation. |
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024PHILADELPHIA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced two presentations at the upcoming American College of Rheumatology (ACR) Convergence 2024, which is being held at the Walter E. Washington Convention Center in Washington, D.C. from November 14-19, 2024. The presentation |
Cabaletta Bio to Participate in Upcoming Investor Conferences in SeptemberPHILADELPHIA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on Wednesday, September 4, 2024 at 4:50 p.m. ET in New York, NY. |
Several Headwinds Dragged Cabaletta Bio (CABA) in Q2Fred Alger Management, an investment management company, released its “Alger Small Cap Growth Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. U.S. equities rose during the second quarter of 2024, with the S&P 500 up 4.28%. Additionally, large-cap growth stocks saw significant gains in the quarter, while smaller-cap, […] |